Screening for hepatocellular carcinoma in cirrhosis (Q35594964)

9 August 2017

1 reference

title

Screening for hepatocellular carcinoma in cirrhosis (English)

1 reference

9 August 2017

0 references

hepatocellular carcinoma

1 reference

Luigi Bolondi

1

1 reference

9 August 2017

1 December 2003

1 reference

9 August 2017

Journal of Hepatology

1 reference

9 August 2017

39

1 reference

9 August 2017

6

1 reference

9 August 2017

1076-1084

1 reference

Rising incidence of hepatocellular carcinoma in the United States

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Screening for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

An epidemiological perspective on cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Efficacy of a surveillance program for early detection of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Improved survival with screening for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Hepatocellular carcinoma: an epidemiologic view

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

HCC surveillance: Who is the target population?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Liver with hypoechoic nodular pattern as a risk factor for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Irregularity of parenchymal echo patterns of liver analyzed with a neural network and risk of hepatocellular carcinoma in liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Liver cell dysplasia: a premalignant condition

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Preneoplastic cellular changes in liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alfa fetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Urinary transforming growth factor beta1 levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Detection of MAGE-4 protein in the sera of patients with hepatitis-C virus-associated hepatocellular carcinoma and liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Small hepatocellular carcinoma in patients undergoing liver transplantation: detection with CT after injection of iodized oil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Hepatocellular carcinoma: is current therapy really altering outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Survival of women ages 40-49 years with breast carcinoma according to method of detection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Critical care issues in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Costs of Breast Cancer and the Cost-Effectiveness of Breast Cancer Screening

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

The new liver allocation system: moving toward evidence-based transplantation policy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900349-0

7 January 2021

10.1016/S0168-8278(03)00349-0

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14642630